Italia markets close in 1 hour 32 minutes

FTSE MIB
34.663,20
+323,88(+0,94%)
Dow Jones
39.561,41
+173,65(+0,44%)
Nasdaq
16.423,76
+77,50(+0,47%)
Nikkei 225
38.229,11
+155,13(+0,41%)
Petrolio
79,70
+0,44(+0,56%)
Bitcoin EUR
58.441,70
+1.811,53(+3,20%)

NVCR May 2024 12.500 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,0500

0,0000

(0,00%)

In data: 11:44AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in